Ghana

Population 2018 30 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>44 (21–75)</td>
<td>148 (72–251)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>8.6 (4.1–15)</td>
<td>29 (14–49)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence</td>
<td>0.87 (0.41–1.5)</td>
<td>2.9 (1.4–5)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>11 (4.8–19)</td>
<td>36 (16–64)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>4.8 (2.3–8.1)</td>
<td>16 (7.7–27)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases 1.3% (1–1.6)
Previously treated cases 16% (14–19)

TB case notifications, 2018

Total new and relapse 13,874
- % tested with rapid diagnostics at time of diagnosis 60%
- % with known HIV status 93%
- % pulmonary 92%
- % bacteriologically confirmed** 66%
- % children aged 0–14 years 6%
- % women 30%
- % men 64%
Total cases notified 14,289

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 32% (19–65)
TB patients facing catastrophic total costs, 2016 64% (61–68)
TB case fatality ratio (estimated mortality/estimated incidence), 2018 39% (14–68)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive 2,509 19%
- on antiretroviral therapy 1,155 46%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance***
- New cases 93%
- Previously treated cases 100%

Laboratory-confirmed cases* MDR/RR-TB: 231, XDR-TB: 1
Patients started on treatment** MDR/RR-TB: 147, XDR-TB: 1

MDR/RR-TB cases tested for resistance to second-line drugs 68

Treatment success rate and cohort size

New and relapse cases registered in 2017 85% 14,121
Previously treated cases, excluding relapse, registered in 2017 82% 429
HIV-positive TB cases registered in 2017 77% 2,759

MDR-RR-TB cases started on second-line treatment in 2016 62% 77
XDR-TB cases started on second-line treatment in 2016 0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions) 20
Funding source: 13% domestic, 47% international, 40% unfunded

Ranges represent uncertainty intervals
* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-02-15 Data: www.who.int/tb/data